Pharmaceuticals

Pharmacogenetic Testing Market Outlook 2026–2030: Key Business Drivers and Trends

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pharmacogenetic testing market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Pharmacogenetic Testing Market between 2026 and 2030?

The pharmacogenetic testing market has seen rapid expansion in recent years. It is projected to grow from $14.33 billion in 2025 to $16.58 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.7%. Historically, this market’s expansion was propelled by advancements in genomic sequencing technologies, concerns regarding adverse drug reactions, an increasing burden of chronic diseases, decreasing genetic testing expenses, and improved clinical awareness.

The pharmacogenetic testing market is projected to experience swift expansion in the coming years. Its valuation is anticipated to reach $29.55 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.5%. This anticipated growth during the forecast period can be primarily attributed to factors such as the rise of precision healthcare, the broadening of direct-to-consumer testing options, the incorporation of these tests with electronic health records, augmented regulatory backing, and increased financial commitment to genomics research. Key trends projected for this period encompass the escalating acceptance of personalized medicine, the expanding application of genetic testing in choosing drugs, the widening scope of its use in oncology and cardiology, an increasing need for accurate diagnostics, and the incorporation of pharmacogenomics into routine clinical practice.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19139&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Pharmacogenetic Testing Market?

The projected expansion of the pharmacogenetic testing market is anticipated to be fueled by the growing need for personalized medicine. This approach, also known as precision medicine, involves customizing healthcare interventions and choices based on an individual’s distinct genetic makeup, biological traits, and lifestyle. Its increasing appeal stems from its capacity to enhance treatment efficacy, facilitate prompt diagnoses, and improve the economic efficiency of patient care. The pharmacogenetic testing market plays a crucial role in personalized medicine by examining genetic profiles to forecast how individuals will respond to drugs, thereby allowing for better treatment choices and minimizing the likelihood of negative side effects. As an illustration, in February 2024, data from the US-based non-profit, Personalized Medicine Coalition (PMC), indicated that the FDA cleared 16 new personalized therapies for rare disease patients in 2023, a significant rise from 6 approvals in 2022. Consequently, the escalating demand for personalized medicine serves as a key impetus for the expansion of the pharmacogenetic testing market.

How Is The Pharmacogenetic Testing Market Organized Into Various Segments?

The pharmacogenetic testing market covered in this report is segmented –

1) By Type: Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, Single Gene Tests

2) By Drug Type: Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, Over-The-Counter Medications

3) By Therapeutic Area: Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology And Hypersensitivity, Dermatology, Gynecology, Oncology, Other Therapeutic Areas

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, Direct-to-Customer Services

5) By End User: Healthcare Providers, Pharmaceutical And Biotechnology Companies, Centers And Academic Institutes, Other End Users

Subsegments:

1) By Whole Genome Sequencing: Illumina Sequencing, Ion Torrent Sequencing, Pacific Biosciences Sequencing, Oxford Nanopore Sequencing

2) By Whole Exome Sequencing: Capture-Based Exome Sequencing, Targeted Enrichment Exome Sequencing, Hybridization-Based Exome Sequencing

3) By Array-Based Tests: SNP Array Testing, Expression Array Testing, Copy Number Variation Array Testing

4) By Single Gene Tests: Targeted Gene Panels, Mutation Detection Tests, Sequencing Of Specific Genes

Which Market Trends Are Opening Growth Opportunities In The Pharmacogenetic Testing Market?

Leading entities within the pharmacogenetics testing market are concentrating on creating sophisticated pharmacogenomics testing offerings, including prescription-ordered pharmacogenetic tests, with the aim of boosting medication safety, refining treatment accuracy, and facilitating individualized therapeutic choices. This type of testing, where genetic analyses are requested by qualified healthcare professionals, investigates how a person’s genetic composition impacts their reaction to particular drugs. This enables clinicians to fine-tune drug choices and dosages, thereby lessening the chance of unfavorable drug responses. As an illustration, in May 2023, UCSF, a US-based healthcare institution, introduced its pharmacogenomics testing service. This service is designed to elevate the accuracy of medical interventions by furnishing healthcare professionals with genetic data that assists in customizing drug regimens for each patient’s distinct profile, enhancing drug effectiveness, and mitigating the potential for detrimental side effects.

Who Are The Major Companies Operating In The Pharmacogenetic Testing Market?

Major companies operating in the pharmacogenetic testing market are CVS Health Corporation, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Eurofins Scientific Inc., Bio-Rad Laboratories, Precision Medicine Advsiors, Azenta Life Sciences, Fulgent Genetics, Pacific Biosciences of California Inc., Castle Biosciences, 23andMe Holding Co., Helix Inc., Genomind Inc., MD Labs, Sonic Genetics, AutoGenomics Inc., LabClinics SA, Gene By Gene Ltd., Xcode Life Sciences, YouScript, RxGenomix LLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pharmacogenetic-testing-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Pharmacogenetic Testing Market?

Asia-Pacific was the largest region in the pharmacogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pharmacogenetic Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19139&type=smp

Browse Through More Reports Similar to the Global Pharmacogenetic Testing Market 2026, By The Business Research Company

Neurogenetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Genetic Toxicology Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/genetic-toxicology-testing-global-market-report

Genetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795